Extended Data Table 1.

Generalized Linear Mixed Model (GLMM) Results for Primary Outcomes of the SWEETSTONE trial

Generalized Linear Mixed Model (GLMM) results for the primary analysis of Calcium oxalate (CaOx), Calcium phosphate (CaP) and uric acid (UA) relative supersaturation (RSR) values measured after treatment with placebo and empagliflozin in participants with calcium kidney stones (left panel) and uric acid (UA) kidney stones (right panel). The GLMM was fitted with a Gamma distribution and a log link function to account for the skewed, non-normal distribution of the data. Treatment and treatment-period were included as fixed effects, whereas patient was included as a random intercept. Analysis of primary outcomes was accompanied by p-values and hypothesis testing with a two-sided significance level of 0.02. The analysis was performed on the per protocol (PP) set. Sample size of the per protocol set was n = 25 for participants with calcium kidney stones and n = 21 for participants with UA kidney stones. exp (coef), exponential coefficient estimates. The exact p-value for treatment effect for RSR CaP in calcium kidney stone formers is = 0.0000315086.